Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct;27(10):e70257.
doi: 10.1111/codi.70257.

Clinical nodal staging to assess the risk of local recurrence after rectal cancer resection: A nationwide cross-sectional study

Mirthe Ubink  1   2 , Eline G M van Geffen  3   4 , Tania C Sluckin  3   4 , Sanne-Marije J A Hazen  3   4 , Karin Horsthuis  4   5 , Joost Nederend  6 , Regina G H Beets-Tan  7   8   9 , Martijn P W Intven  10 , Cornelis Verhoef  1 , Miranda Kusters  3   4 , Pieter J Tanis  1   4   11 ; Dutch Snapshot Research Group
Collaborators, Affiliations

Clinical nodal staging to assess the risk of local recurrence after rectal cancer resection: A nationwide cross-sectional study

Mirthe Ubink et al. Colorectal Dis. 2025 Oct.

Abstract

Aim: In rectal cancer, neo-adjuvant (chemo)radiotherapy (n(C)RT) should be used selectively, due to related toxicity. The decision to offer n(C)RT is mainly based on preoperative MRI staging. cN category has limited accuracy and its use when deciding on n(C)RT is controversial. This population-based study aimed to assess the association between cN category and local recurrence (LR) rate.

Method: Data from a national cross-sectional cohort of patients who underwent curative resection of primary rectal cancer in the Netherlands in 2016 were used. Patients were subdivided by neo-adjuvant treatment strategy: no n(C)RT, short-course RT with short interval to surgery (SCRT-SI) or downstaging therapy (SCRT with long interval to surgery, CRT, total neoadjuvant therapy or chemotherapy only). The 4-year LR rate was calculated per (y)cN category and corrected for known pre-operative confounders in Cox-regression analysis.

Results: Of 2148 included patients, 1000 received no n(C)RT, 449 SCRT-SI and 699 downstaging therapy. Median follow-up was 50 months (interquartile range [IQR] 38-55). The 4-year LR rates for cN0, cN1 and cN2 were 6.3%, 5.0% and 6.2% without n(C)RT, and 0%, 2.4% and 0% after SCRT-SI. In patients treated with downstaging therapy, not primary cN, but restaging ycN category was significantly associated with LR rate (9.1%, 17.4% and 18.5%; p = 0.006) in univariable analysis. In multivariable analysis, no association was observed between ycN and LR (p = 0.088).

Conclusion: Evaluation of nationwide clinical practice did not reveal significant associations between cN category and LR rate after rectal cancer resection within three neo-adjuvant treatment groups, which questions its validity for clinical decision-making.

Keywords: MRI staging; cN category; local recurrence; neoadjuvant therapy; rectal cancer.

PubMed Disclaimer

Conflict of interest statement

None declared.

Figures

FIGURE 1
FIGURE 1
Flowchart of patient inclusion.
FIGURE 2
FIGURE 2
The influence of cN category on MRI on local recurrence: (A) Four‐year local recurrence rate for patients without neo‐adjuvant (chemo)radiotherapy for cN0 (6.3%), cN1 (5.0%) and cN2 (6.2%), p = 0.817, (B) Four‐year local recurrence rate for patients treated with 5 × 5 Gy short interval for cN0 (0%), cN1 (2.4%) and cN2 (0%), p = 0.331, (C) Four‐year local recurrence rate for patients treated with downstaging neo‐adjuvant therapy for cN0 (14.3%), cN1 (9.3%), cN2 (13.9%), p = 0.169, (D) Four‐year local recurrence rate for patients treated with downstaging neo‐adjuvant therapy for ycN0 (9.1%), ycN1 (17.4%), ycN2 (18.5%), p = 0.006.
See this image and copyright information in PMC

References

    1. Kapiteijn E, Putter H, van de Velde CJH, Cooperative Investigators of the Dutch ColoRectal Cancer Group . Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands. Br J Surg. 2002;89(9):1142–1149. - PubMed
    1. Peeters KCMJ, Marijnen CAM, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, et al. The TME trial after a median follow‐up of 6 years – increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007;246(5):693–701. - PubMed
    1. Tocchi A, Mazzoni G, Lepre L, Liotta G, Costa G, Agostini N, et al. Total mesorectal excision and low rectal anastomosis for the treatment of rectal cancer and prevention of pelvic recurrences. Arch Surg. 2001;136(2):216–220. - PubMed
    1. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–1740. - PubMed
    1. Floris SV, Dana MO, Hannah W, Sabrina TL, Li‐Xuan Q, James TB, et al. Long‐term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial. J Clin Oncol. 2024;42(5):500–506. - PMC - PubMed

MeSH terms

Grants and funding

LinkOut - more resources